Navigation Links
Diseased Heart Valve Replaced Through Small Chest Incision
Date:2/9/2009

New procedure prospective option for patients too frail for open-heart surgery

CHICAGO, Feb 9 /PRNewswire-USNewswire/ -- When 91-year-old Irvin Lafferty was diagnosed with severe blockage of his heart valve -- hardening that is formally known as aortic valve stenosis -- open-heart surgery was out of the question. He'd already survived quadruple bypass while in his 50s, and having lived almost a century, Lafferty wasn't a good candidate for heart surgery for many reasons. His local cardiologist referred him to surgical and interventional specialists at Chicago's Bluhm Cardiovascular Institute of Northwestern Memorial Hospital. And, on January 21, 2009, Lafferty became the first patient in Illinois to receive a prosthetic heart valve through a procedure known as transapical transcatheter aortic valve implantation, which combines catheterization technology and traditional surgery, allowing doctors to implant a new heart valve in place of Lafferty's diseased valve while his heart remained beating.

"Traditional open-heart surgery is a very safe and effective way to replace diseased heart valves, but for many patients bypass surgery is not a viable option," says Patrick M. McCarthy, MD, Northwestern Memorial's chief of cardiothoracic surgery and co-director of its Bluhm Institute and a Heller-Sacks professor of surgery at Northwestern University's Feinberg School of Medicine. "By utilizing the percutaneous technique -- meaning surgery is not required -- we are able to greatly reduce risk for these patients. We see percutaneous valve repair as not only having a great impact upon how high-risk patients are treated, but in how heart valve disease is treated period, in the U.S. and around the world."

McCarthy is a co-principal investigator for the clinical trial that provided Lafferty's new heart valve, which is formally referred to as the Placement of AoRTic TraNscathetER Valve, or PARTNER. The Bluhm Institute is among the trial's pioneering sites. McCarthy says the procedure builds upon a routine catheter-based procedure, the balloon aortic valvuloplasty.

"Balloon aortic valvuloplasty has been traditionally offered as a palliative therapy for patients who were not candidates for aortic valve surgery," said the hospital's Director of the Cardiac Catheterization Laboratory Charles J. Davidson, MD, who is also a co-principal investigator for the trial and a professor of medicine at Northwestern University's Feinberg School of Medicine. "This particular technique is a more durable treatment than balloon valvuloplasty and is potentially a breakthrough for treating high-risk patients."

Medical experts estimate every year nearly 200,000 people in the U.S. need new heart valves. Yet over half of them do not receive them primarily due to frailty, one of the most common reasons for exclusion from traditional open-heart surgery.

"Surgery becomes far too risky when patients are conditionally weak or frail," says Chris Malaisrie MD, a Northwestern Memorial cardiac surgeon and member of the site team evaluating this new procedure. "The goal is to replace diseased valve at minimal risk to these patients--many of whom have very limited therapeutic options. Aortic valve replacement is one of few therapies offering both symptomatic relief and improved long-term survival."

During insertion, the artificial valve remains collapsed until it reaches its destination. It is then expanded and released in place of diseased aortic heart valves. The prosthesis is made of stainless steel and biological leaflets that help direct the flow of blood in the heart. It is permanent and integrates an expandable stent that holds the valve in its intended position. Northwestern Memorial utilizes both the transfemoral (through the groin) and transapical (through the ribs) approaches. Implantation occurs in a hybrid operating room suite that incorporates elements of both a traditional OR and catheterization laboratory.

For more information about the Bluhm Cardiovascular Institute and the treatment of aortic valve stenosis please visit us online at http://www.nmh.org/heart. Participation in the PARTNER study will last a minimum of five years. For more information about the trial contact Kerry Madden, RN, at the Bluhm Institute's Clinical Trials Unit at (312) 695-1806 or kmadden@nmh.org.

Dr. Patrick McCarthy, the Principal Investigator for this study, is a consultant for Edwards Lifesciences (for valve repair, not the study device used in the PARTNER trial), the manufacturer of the investigational valve. In addition, Dr. McCarthy receives royalties from 3 annuloplasty rings developed with Edwards (Edwards MC3 tricuspid system, Myxo ETlogix, and the Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring [CMA IMR ring].)

About Northwestern Memorial Hospital

Northwestern Memorial Hospital is one of the country's premier academic medical centers and is the primary teaching hospital of the Northwestern University Feinberg School of Medicine. Along with its Prentice Women's Hospital and Stone Institute of Psychiatry, the hospital comprises 873 beds, 1,554 affiliated physicians and 6,747 employees. Northwestern Memorial is recognized for providing exemplary patient care and state-of-the art advancements in the areas of cardiovascular care; women's health; oncology; neurology and neurosurgery; solid organ and soft tissue transplants and orthopaedics.

Northwestern Memorial possesses nursing Magnet Status, the nation's highest recognition for patient care and nursing excellence, and it is listed in 10 clinical specialties in U.S. News & World Report's 2008 "America's Best Hospitals" guide. For nine years running, it has been rated among the "100 Best Companies for Working Mothers" guide by Working Mother magazine. The hospital is a recipient of the prestigious National Quality Health Care Award and has been chosen by Chicagoans as their "most preferred hospital" according to the National Research Corporation's annual survey for 10 years.


'/>"/>
SOURCE Northwestern Memorial Hospital
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tumor-killing virus selectively targets diseased brain cells
2. Physicians Hail VNUS Device for Closing Diseased Perforating Veins
3. Bayer Consumer Care Joins Forces with WomenHeart to Fight Heart Disease
4. Tributes.com Launches Light a Candle Program In Support of the American Heart Association and Heart Health Month
5. The Childrens Heart Foundation to Support National Congenital Heart Coalition (NCHC) on Capitol Hill by Participating in National Congenital Heart Lobby Day on February 10
6. WomenHeart Celebrates American Heart Month With Heart Promises Campaign
7. National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure
8. Leading Spring Water Brands From Nestle Waters Team Up With the American Heart Association START! Initiative
9. Scientists Heartened at Prospect of End to Stem Cell Ban
10. Valentines Day Indulgences Can Be Heart Healthy
11. Genetic Test for Heart Disease Risk in the Works
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
Breaking Medicine Technology: